Centrosomal cohesion deficits in peripheral lymphoblastoid cells from G2019S LRRK2-PD patients, reversible by LRRK2 inhibitors. Proposed as a cellular biomarker for patient stratification. This evidence concerns the gene LRRK2 and Parkinson disease.